Silevertinib

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

Black Diamond said the results underpin a randomized glioblastoma study slated for 2026, with progression-free survival readouts in NSCLC still to come.